GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Karo Pharma AB (OTCPK:KARBF) » Definitions » Other Operating Expense

Karo Pharma AB (Karo Pharma AB) Other Operating Expense : $-0.7 Mil (TTM As of Jun. 2022)


View and export this data going back to . Start your Free Trial

What is Karo Pharma AB Other Operating Expense?

Karo Pharma AB's Other Operating Expense for the three months ended in Jun. 2022 was $0.0 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Jun. 2022 was $-0.7 Mil.

Karo Pharma AB's quarterly Other Operating Expense increased from Sep. 2021 ($-3.3 Mil) to Dec. 2021 ($1.8 Mil) but then declined from Dec. 2021 ($1.8 Mil) to Jun. 2022 ($0.0 Mil).

Karo Pharma AB's annual Other Operating Expense increased from Dec. 2019 ($-0.7 Mil) to Dec. 2020 ($-0.7 Mil) and increased from Dec. 2020 ($-0.7 Mil) to Dec. 2021 ($-0.6 Mil).


Karo Pharma AB Other Operating Expense Historical Data

The historical data trend for Karo Pharma AB's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Karo Pharma AB Other Operating Expense Chart

Karo Pharma AB Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.12 -0.09 -0.75 -0.70 -0.64

Karo Pharma AB Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Jun22
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.06 2.83 -3.31 1.83 -

Karo Pharma AB Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Karo Pharma AB Other Operating Expense Related Terms

Thank you for viewing the detailed overview of Karo Pharma AB's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Karo Pharma AB (Karo Pharma AB) Business Description

Traded in Other Exchanges
N/A
Address
Klara Norra Kyrkogata 33, Stockholm, SWE, 111 22
Karo Pharma AB is a healthcare corporation. It is engaged in the business activity of developing and marketing products to pharmacies and directly to the healthcare sector. The trademarks of the firm are Ibux, Paracet, Dosett, Allevo, and Swereco. It operates in the segment of development and sale of products to pharmacies, digital distribution channels and food stores. The company carries its business operations in Sweden and internationally, of which the majority of the revenue is generated from Sweden and Norway.

Karo Pharma AB (Karo Pharma AB) Headlines

From GuruFocus

Avista Capital Partners To Sell Trimb To Karo Pharma

By PRNewswire PRNewswire 06-25-2019